StemCell Therapy

The month of May 2020 was an exciting month for oncology with many updates from the FDA. In particular, the FDA granted 4 approvals on Friday, May 15, 2020 alone. Eight additional approvals were granted throughout the month. Among other FDA news this month, the FDA granted a Priority Review, 2 Orphan Drug designations, a Breakthrough Therapy designation, a Fast Track designation, a Regenerative Medicine Advanced Therapy designation, and more.

FDA Approves EIS System Nevisense 3.0 for the Early Detection of Melanoma

On May 1, 2020, the FDA granted approval to an electrical impedance spectroscopy system, Nevisense 3.0, the third-generation of the SciBase Nevisense system, for the early detection of melanoma. Nevisense uses an AI-based point-of-care system for a non-invasive procedure to evaluate irregular moles and is the only FDA-approved system available in the United States for the detection of melanoma.

FDA Grants Priority Review to Oral Hypomethylating Agent for Frontline Maintenance in AML

The FDA granted Priority Review on May 1, 2020, to an investigational oral hypomethylating agent, CC-486, as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a complete remission (CR) or CR with incomplete blood count recovery after receiving induction therapy with or without consolidation therapy.

FDA Grants Orphan Drug Designation to HQP1351 in Chronic Myeloid Leukemia

On May 4, 2020, the FDA granted an Orphan Drug designation to a third-generation BCR-ABL inhibitor, HQP1351, as treatment of patients with chronic myeloid leukemia.

FDA Extends Target Action Date for Liso-cel in R/R Large B-cell Lymphoma

The action date for the CD19-directed chimeric antigen receptor (CAR) T cell therapy lisocabtagene maraleucel (liso-cel) as treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least 2 therapies, was extended 3 months by the FDA. The updated Prescription Drug User Fee Act (PDUFA) action date is November 16, 2020, according to an announcement on May 6, 2020.

FDA Grants Orphan Drug Designation to First Liver-Targeted Drug for HCC

On May 6, 2020, MIV-818, was granted an Orphan Drug Designation by the FDA for the treatment of patients with hepatocellular carcinoma, which follows an Orphan Medicinal Drug designation in Europe for the same indication, which was granted in April 2020 by the Committee for Orphan Medicinal Products, a division of the European Medicines Agency.

FDA Approves Capmatinib in MET Exon 14+ Metastatic Non-Small Cell Lung Cancer

The FDA granted approval on May 6, 2020, to capmatinib (Tabrecta) for adult patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test.

FDA Grants RMAT Designation to Ilixadencel in Metastatic RCC

On May 8, 2020, the FDA granted a Regenerative Medicine Advanced Therapy designation to ilixadencel, as treatment of metastatic renal cell carcinoma.

FDA Approves Maintenance Olaparib/Bevacizumab in Advanced Ovarian Cancer

The FDA granted approval on May 8, 2020, to the combination of olaparib (Lynparza) and bevacizumab (Avastin) for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiencypositive status defined by either a deleterious or suspected deleteriousBRCAmutation, and/or genomic instability.

FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers

On May 9, 2020, the FDA approved selpercatinib (formerly known as LOXO-292; Retevmo) capsules for the treatment of patients with lung cancer or thyroid cancer harboringRETalterations, marking the first treatment approved by the FDA to targetRETgene alterations.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan in HER2+ Gastric Cancer

The FDA granted a Breakthrough Therapy designation on May 11, 2020, to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received 2 or more prior regimens including trastuzumab.

FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data

On May 13, 2020, the FDA issued a Refusal to File letter regarding the Biologics License Application for the CAR T-cell agent, idecabtagene vicleucel (ide-cel), which was submitted in March 2020 as a potential treatment for patients with heavily pretreated relapsed or refractory multiple myeloma. A preliminary review was carried out by the FDA, but it was realized that the Chemistry, Manufacturing, and Control module of the BLA required more information before the review could be completed.

FDA Denies Approval of Avapritinib in Fourth-Line GIST

The FDA issued a complete response letter (CRL) to Blueprint Medicines, Inc regarding the New Drug Application for avapritinib (Ayvakit) as treatment of adult patients with unresectable or metastatic fourth-line gastrointestinal stromal tumor. The CRL denies approval of the application.

FDA Approves Pomalidomide for Treatment of Kaposi Sarcoma

On May 15, 2020, the FDA granted approval to pomalidomide (Pomalyst) for the treatment of patients with acquired immunodeficiency syndromesrelated Kaposi sarcoma who have developed resistance to highly active antiretroviral therapy, or those with Kaposi sarcoma who are human immunodeficiency virusnegative.

FDA Approves Nivolumab/Ipilimumab Combo for Advanced PD-L1+ NSCLC

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) on May 15, 2020, for the treatment of patients with metastatic or recurrent NSCLC whose tumors express PD-L1 (1%), as determined by an FDA-approved test, and who do not have anEGFRorALKtumor aberration.

FDA Approves Rucaparib for BRCA1/2-Mutant mCRPC

On May 15, 2020, the FDA has approved rucaparib (Rubraca) the treatment of adult patients with a deleteriousBRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

Ripretinib Receives FDA Approval for Treatment of Advanced GIST

On May 15, 2020, the FDA has granted approval to ripretinib (Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor who had at least 3 prior lines of therapy with kinase inhibitors, including imatinib (Gleevec). The approval is 3 months ahead of the Prescription Drug Fee Act target action date.

FDA Approves Atezolizumab Monotherapy in Advanced PD-L1-High NSCLC

The FDA granted approval on May 18, 2020, to atezolizumab (Tecentriq) monotherapy as treatment for adults with metastatic nonsmall cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining on 50% of tumor cells [TC 50%] or PD-L1 staining on tumor-infiltrating immune cells [IC] covering 10% of the tumor area [IC 10%]), as determined by an FDA-approved test, and have noEGFRorALKgenomic tumor aberrations. This approval marks the fifth indication for atezolizumab in metastatic NSCLC and lung cancer in general, Genentech announced in a press release.

Trastuzumab Deruxtecan Receives Orphan Drug Designation from FDA for Gastric Cancer

The FDA granted an Orphan Drug designation to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with gastric or gastroesophageal junction cancer on May 22, 2020.

FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC

On May 22, 2020, the FDA has granted approval to brigatinib (Alunbrig) for the frontline treatment of patients withALK-positive metastatic NSCLC, as detected by an FDA-approved test.

FDA Approves Frontline Nivolumab/Ipilimumab/Chemo for Advanced NSCLC

The FDA has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) with limited platinum-doublet chemotherapy for the frontline treatment of patients with metastatic or recurrent NSCLC who do not have EGFR or ALK genomic tumor aberrations, according to an announcement on May 26, 2020.

FDA Cancels ODAC Meeting for BLA of Margetuximab in HER2+ Breast Cancer

On May 28, 2020, the FDA has announced that they will no longer hold an Oncologic Drugs Advisory Committee meeting to discuss the Biologics License Application for margetuximab (MGAH22) in combination with chemotherapy as a potential treatment of patients with HER2-positive breast cancer. However, the FDA still plans to meet the Prescription Drug User Fee Act date of December 18, 2020, for the application review.

Onvansertib Receives FDA Fast Track Designation in KRAS+ mCRC

The FDA granted a Fast Track designation to onvansertib for the second-line treatment of patients withKRAS-mutant metastatic colorectal cancer in combination with FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) and bevacizumab (Avastin) on May 28, 2020.

FDA Approves Atezolizumab Combo for Unresectable or Metastatic Hepatocellular Carcinoma

The FDA granted approval to atezolizumab in combination with bevacizumab as treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not had a prior systemic therapyon May 29, 2020.

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review

Pralsetinib (BLU-667) was granted a priority review on May 29, 2020, for the treatment of patients with advanced solid tumors harboring RETalterations, with a plannedaction date of November 23, 2020.

FDA Approves Frontline Ramucirumab/Erlotinib for EGFR+ mNSCLC

The FDA approved ramucirumab (Cyramza) in combination with erlotinib (Tarceva) for the first-line treatment of patients with metastatic NSCLC harboringEGFRexon 19 deletions or exon 21 (L858R) mutations on May 30, 2020, marking this the only antiVEGFR/EGFR tyrosine kinase inhibitor combination regimen approved by the FDA for the treatment of patients withEGFR-mutant metastatic NSCLC.

Follow this link:
A Look Back at the FDA News from May 2020 - Targeted Oncology

This entry was posted on June 8, 2020 at 12:44 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |